AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie pPI: Pharmaceutical Preparation Manufacturing (Index Dec 1981=100)
FRED (PCU325412325412)
Latest, Q2 2026
926.70
Period ended Jun 30, 2026
Change on a year earlier
+1.3%
915.10 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
1
FRED (PCU325412325412)
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | PPI: Pharmaceutical Preparation Manufacturing (Index Dec 1981=100) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 926.70 | +1.3% | FRED (PCU325412325412) ↗ |
| Q1 2026 | Mar 31, 2026 | 925.40 | +1.1% | FRED (PCU325412325412) ↗ |
| Q4 2025 | Dec 31, 2025 | 919.10 | +0.1% | FRED (PCU325412325412) ↗ |
| Q3 2025 | Sep 30, 2025 | 917.40 | 0.0% | FRED (PCU325412325412) ↗ |
| Q2 2025 | Jun 30, 2025 | 915.10 | +0.1% | FRED (PCU325412325412) ↗ |
| Q1 2025 | Mar 31, 2025 | 915.30 | +0.8% | FRED (PCU325412325412) ↗ |
| Q4 2024 | Dec 31, 2024 | 918.10 | +2.4% | FRED (PCU325412325412) ↗ |
| Q3 2024 | Sep 30, 2024 | 917.30 | +2.3% | FRED (PCU325412325412) ↗ |
| Q2 2024 | Jun 30, 2024 | 914.40 | +2.3% | FRED (PCU325412325412) ↗ |
| Q1 2024 | Mar 31, 2024 | 907.80 | +1.8% | FRED (PCU325412325412) ↗ |
| Q4 2023 | Dec 31, 2023 | 896.30 | +2.9% | FRED (PCU325412325412) ↗ |
| Q3 2023 | Sep 30, 2023 | 896.50 | +3.3% | FRED (PCU325412325412) ↗ |
| Q2 2023 | Jun 30, 2023 | 894.10 | +4.5% | FRED (PCU325412325412) ↗ |
| Q1 2023 | Mar 31, 2023 | 892.00 | +5.3% | FRED (PCU325412325412) ↗ |
| Q4 2022 | Dec 31, 2022 | 871.30 | +4.4% | FRED (PCU325412325412) ↗ |
| Q3 2022 | Sep 30, 2022 | 868.20 | +4.2% | FRED (PCU325412325412) ↗ |
| Q2 2022 | Jun 30, 2022 | 855.30 | +2.4% | FRED (PCU325412325412) ↗ |
| Q1 2022 | Mar 31, 2022 | 847.30 | +1.6% | FRED (PCU325412325412) ↗ |
| Q4 2021 | Dec 31, 2021 | 834.30 | +1.7% | FRED (PCU325412325412) ↗ |
| Q3 2021 | Sep 30, 2021 | 832.90 | +1.2% | FRED (PCU325412325412) ↗ |
| Q2 2021 | Jun 30, 2021 | 835.00 | +1.2% | FRED (PCU325412325412) ↗ |
| Q1 2021 | Mar 31, 2021 | 833.80 | +0.9% | FRED (PCU325412325412) ↗ |
| Q4 2020 | Dec 31, 2020 | 820.60 | +1.2% | FRED (PCU325412325412) ↗ |
| Q3 2020 | Sep 30, 2020 | 823.00 | +1.2% | FRED (PCU325412325412) ↗ |
| Q2 2020 | Jun 30, 2020 | 824.70 | +1.8% | FRED (PCU325412325412) ↗ |
| Q1 2020 | Mar 31, 2020 | 826.20 | +2.0% | FRED (PCU325412325412) ↗ |
| Q4 2019 | Dec 31, 2019 | 810.60 | +2.2% | FRED (PCU325412325412) ↗ |
| Q3 2019 | Sep 30, 2019 | 813.10 | +3.1% | FRED (PCU325412325412) ↗ |
| Q2 2019 | Jun 30, 2019 | 810.50 | +3.6% | FRED (PCU325412325412) ↗ |
| Q1 2019 | Mar 31, 2019 | 810.20 | +3.5% | FRED (PCU325412325412) ↗ |
| Q4 2018 | Dec 31, 2018 | 793.00 | +3.6% | FRED (PCU325412325412) ↗ |
| Q3 2018 | Sep 30, 2018 | 788.60 | +4.1% | FRED (PCU325412325412) ↗ |
| Q2 2018 | Jun 30, 2018 | 782.50 | +4.0% | FRED (PCU325412325412) ↗ |
| Q1 2018 | Mar 31, 2018 | 783.10 | +4.7% | FRED (PCU325412325412) ↗ |
| Q4 2017 | Dec 31, 2017 | 765.80 | +6.0% | FRED (PCU325412325412) ↗ |
| Q3 2017 | Sep 30, 2017 | 757.70 | +5.4% | FRED (PCU325412325412) ↗ |
| Q2 2017 | Jun 30, 2017 | 752.60 | +6.0% | FRED (PCU325412325412) ↗ |
| Q1 2017 | Mar 31, 2017 | 748.10 | +6.1% | FRED (PCU325412325412) ↗ |
| Q4 2016 | Dec 31, 2016 | 722.40 | – | FRED (PCU325412325412) ↗ |
| Q3 2016 | Sep 30, 2016 | 719.00 | – | FRED (PCU325412325412) ↗ |
| Q2 2016 | Jun 30, 2016 | 709.90 | – | FRED (PCU325412325412) ↗ |
| Q1 2016 | Mar 31, 2016 | 705.20 | – | FRED (PCU325412325412) ↗ |
Cite this data
StockData. (2026). AbbVie PPI: Pharmaceutical Preparation Manufacturing (Index Dec 1981=100), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/fred_ppi_pharma
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.